B
Bull
Bull · 25%RENB
$0.38
シナリオ価格
$1.420
+0.173 (+12.16%)終値時点
Loading chart…
- High
- 1.430
- Open
- 1.190
- VWAP
- 1.33
- Vol
- 896.30K
- Mkt Cap
- 230.89M
- Low
- 1.130
- Amount
- 1.19M
- EV/EBITDA, TTM
- 0.00
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
バリュエーション指標
The current forward P/E ratio for Lunai Bioworks Inc (RENB) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for RENB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
イベントタイムライン
ニュース
2.009-28TipRanksStock Splits Scheduled for This Week (September 29 to October 3) – Keep Your Investments Active
8.509-25BenzingaPepGen Shares Surge 112%; Check Out 20 Stocks Making Moves in Premarket Trading
3.009-09BenzingaThree Health Care Stocks You Won't Want to Overlook in Q3
8.508-19GlobenewswireInvestor Alert from Former Louisiana Attorney General: Kahn Swick & Foti, LLC Examines Price and Process in Predictive Oncology Inc. (POAI) Proposed Sale
8.007-29PRnewswireAI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
RENB FAQ — answered by Alphio AI
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。